Redcare Pharmacy Q1 prescription sales surge 55%, shares jump 15% By Investing.com

Redcare reported German prescription revenue +55% YoY to €168m (consensus €162m) and group revenue +18.3% to €848m (consensus €837m); shares jumped ~14% to €40.96. Group Rx revenue rose 35% to €315m and non-prescription revenue increased ~10% (group €533m); DACH revenue was €692m (+18.9%), active customers reached 14.2m (+8%), and e-prescription satisfaction improved to 76. Management reiterated 2026 guidance and Jefferies retains a Buy with a €150 target.

Analysis

This quarter’s print should be read as evidence that digital e‑Rx product-market fit is moving from niche to mainstream in DACH, not merely a marketing spike. As e‑prescription satisfaction and active customer cohorts rise, unit economics (LTV/CAC) can inflect materially — meaning each incremental active customer now contributes disproportionately to gross margin once fulfillment density crosses local thresholds. That creates a two‑tier market: scale e‑pharmacies that control fulfillment networks and data-driven retention will see margin expansion, while fragmented independents will face 100–200bp gross margin erosion over 12–24 months as volume shifts online.

Key risks are regulatory and operational. A reimbursement adjustment or tighter pharmacy compensation rules from German insurers (GKV) could remove 200–300bps of gross margin within a 6–18 month window; conversely, a competitor arms‑race in marketing could push CAC back up, delaying payback beyond 12 months. Operationally, rapid volume growth exposes last‑mile capacity and inventory financing — if capex/working capital steps up materially, free cash flow improvement will lag topline for 2–4 quarters.

The market reaction creates a tactical window: the confirmation of guidance lowers near‑term downside but full re‑rating will require visible margin expansion over multiple quarters or a credible roadmap to unit economics improvement (repeat purchase rates, lower fulfilment cost/parcel). For investors, the cleanest way to express asymmetric upside is via a directional long with defined downside protection or a calendar/options structure to monetize upside while capping tail risk. Monitor three catalysts: next two quarters’ gross margin trajectory, reimbursement/regulatory commentary, and incremental fulfillment unit cost per parcel.

Key Decisions for Investors

• Long RDC (ETR:RDC) — size 1–2% notional, target 12‑month total return +30–40%, stop at 12% drawdown. Rationale: buy confirmed growth while guidance reduces near‑term binary risk; need margin tailwinds to justify larger position.
• Buy a protective collar on RDC for 9–12 months — long stock + buy 12‑month put ~15% OTM and sell a 12‑month call ~25–30% OTM to finance the put. Rationale: preserves upside to consensus rerating while capping regulatory/operational tail risk.
• Options play (asymmetric): buy 12‑month LEAP calls ~25% OTM (small notional 0.5–1%) — objective is to capture multi‑quarter re‑rating if margin inflection proves sustainable, with limited cash outlay.
• Event hedge: if gross margin misses next two quarters, reduce exposure and redeploy into logistics/fulfilment enablers (select names providing 3rd‑party last‑mile capacity) — these will see secular demand and can hedge against RDC execution risk.